Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...
MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
Fosun Pharma Launches 20ml SPSB Liquid Product in US Market
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...
Merck’s Gabor Outlines AI and Biomedicine Strategy in China
Allan Gabor, president of Merck KGaA China and executive vice president of Merck Electronics, shared...
Luye Pharma Grants ICI Pakistan Distribution Rights for Schizophrenia Drug Seroquel
China-based Luye Pharma Group has reportedly handed over the distribution and marketing rights for its...
Sino Medical Sciences Gains Approval for Drug-Eluting Stent System
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received market...
Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China
The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...
Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study
China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...
YiChang HEC Reports Strong Recovery in 2022 Interim Results
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...
Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute
Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...
Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...
Ubrigene Raises Hundreds of Millions in Series C Financing Round
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...
China’s First Proton Therapy System Approved by NMPA
The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...
Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
China Resources Pharma Reports Strong Interim Results Amid COVID-19
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...